Erinacine A-enriched Hericium Erinaceus chocolate to augment antidepressant efficacy in major depressive disorder patients
Background
Major depressive disorder (MDD) is a debilitating condition, often managed with antidepressant medications. However, a significant portion of patients experience inadequate response or intolerable side effects, highlighting the need for adjunctive therapies. Emerging research suggests a strong link between gut microbiota dysbiosis, inflammation, and neurochemical imbalances in MDD pathophysiology. Nutrient supplementation, particularly compounds like Erinacine A from Hericium Erinaceus (Lion's Mane mushroom), which may support neurogenesis and modulate gut health, offers a promising avenue to enhance antidepressant outcomes and address underlying biological gaps.
Study Design
This is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate nutrient supplementation's role in augmenting antidepressant efficacy in MDD. 120 subjects, continuing their existing antidepressant regimen, will be randomized into three groups. Participants will receive 3 pieces of chocolate daily for 24 weeks: either LF chocolate, Erinacine A-enriched Hericium Erinaceus chocolate, or a plain chocolate placebo. Primary endpoints include symptom rating, identification of antidepressant-related/depressive disorder-related genome profiles, biomarkers for metabolic indices, psychosocial questionnaires, cognitive function tests, and fecal samples for gut microbiota profiling.
Results
This abstract describes the protocol for a randomized, double-blind, placebo-controlled clinical trial; therefore, no findings are presented at this stage. The study aims to identify alterations in antidepressant-related/depressive disorder-related genome profiles, metabolic indices, psychosocial variables, cognitive function, and gut microbiota profiles over the 24-week period. The comprehensive assessment includes symptom rating, blood samples for genome profiles and biomarkers, questionnaires, cognitive tests, and fecal samples to recognize and distinguish changes in MDD patients' microbiota profiles.
Why It Matters
If successful, this study could establish a novel, accessible adjunctive therapy for major depressive disorder, potentially improving treatment response rates and patient quality of life. For individuals using antidepressants, incorporating a specific nutrient-enriched chocolate could offer a practical, non-pharmacological strategy to enhance therapeutic outcomes. This research also has the potential to elucidate the intricate interplay between gut microbiota, metabolism, and brain health in MDD, paving the way for personalized nutritional interventions. The 24-week duration and comprehensive biomarker assessment could provide robust data for future clinical translation.
major depressive disorder
mdd
erinacine a
hericium erinaceus
lion's mane
gut microbiota